Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China-Reference-Cited by-同舟云学术

Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China

Published:2019-05-02 Issue:1 Volume:19 Page:
ISSN:1471-230X
Container-title:BMC Gastroenterology
language:en
Short-container-title:BMC Gastroenterol

Author:

Sun Jian,Ding Huiguo,Chen Guofeng,Wang Guiqiang,Wei Lai,Zhang Jiming,Xie Qing,Wan Mobin,Tang Hong,Chen Shijun,Gao Zhiliang,Wang Yuming,Zhang Dazhi,Huang Wenxiang,Sheng Jifang,Ning Qin,Yang Dongliang,Lu Jian,Pan Chen,Yang Yuxiu,Wang Jue,Sun Chuanzhen,Wang Qixin,Hou Jinlin

Funder

Merck Sharp & Dohme, Shanghai, China

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12876-019-0981-5.pdf

Reference34 articles.

1. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.

2. Word Health Organization. Hepatitis B. In: Vol; 2014. http://www.who.int/mediacentre/factsheets/fs204/en/ .

3. Lu FM, Zhuang H. Prevention of hepatitis B in China: achievements and challenges. Chin Med J. 2009;122:2925–7.